Tadalafil Tablet
Product Images NDC 68071-2421

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-2421). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2421 6)

Label for Tadalafil 20 mg tablets by NuCare Pharmaceuticals, Inc. The label shows the product name and strength, quantity of 60 tablets, and notes the tablets are film-coated and oval-shaped, debossed with 'T20'. It includes storage instructions, warnings, and regulatory identifiers such as NDC 68071-2421-6 and GTIN. The label features barcodes and a QR code with manufacturing and expiration placeholders.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks between Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change in IPSS score, with Tadalafil showing a greater reduction than placebo over time. A statistical significance marker (p<0.01) is noted at week 12.*

FDA Label Image

Figure1 (Tadalafil Figure1)

Four line graphs depicting the difference in blood pressure (BP) measurements over time between tadalafil and placebo groups. The graphs show changes in standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP over a 96-hour period, with time on the x-axis (in hours) and BP difference on the y-axis (in mmHg). Error bars indicate variability.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs showing the effects of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo plus doxazosin 8 mg on standing and supine systolic blood pressure over 24 hours post-dose. The vertical axis measures blood pressure changes (mmHg), and the horizontal axis shows time post-dose (hours).*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph depicting systolic blood pressure (mmHg) changes over 12 hours after administration of tadalafil (20 mg or 8 mg) and placebo, each combined with 8 mg doxazosin. The x-axis shows time in hours and the y-axis shows systolic BP changes from baseline, illustrating blood pressure trends with different treatment regimens.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for different dosing regimens: single 20-mg tadalafil dose, single 5-mg tadalafil dose, and once-daily 5-mg tadalafil after 5 consecutive days. The graph illustrates concentration changes up to 120 hours post-dose with error bars.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment period. Two groups are compared: Tadalafil 5 mg and placebo. The graph indicates a greater reduction in IPSS score for Tadalafil 5 mg compared to placebo, with statistical significance (p<0.01). The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline in IPSS total score.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph showing change from baseline in IPSS Total Score over treatment duration up to 12 weeks, comparing Tadalafil 5 mg to placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change from baseline. The graph indicates statistically significant differences (p<0.01) between Tadalafil and placebo.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph showing mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride. The vertical axis represents the least squares mean change, while the horizontal axis shows weeks of therapy at 0, 4, 12, and 26 weeks. Two data series are displayed with markers, alongside statistical annotations for significance.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure of Tadalafil, illustrating its complex fused ring system including a benzodioxole moiety and multiple carbonyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.